A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.

被引：0
|
作者：
Millstein, Joshua
Budden, Timothy
Anglesio, Michael
Talhouk, Aline
Beeghly-Fadiel, Alicia
Berchuck, Andrew
Chenevix-Trench, Georgia
deFazio, Anna
Fasching, Peter A.
Gayther, Simon
Garcia, Maria
Goode, Ellen L.
Henderson, Michelle
Konecny, Gottfried E.
Orsulic, Sandra
Huntsman, David
Bowtell, David
Doherty, Jennifer
Pharoah, Paul
Ramus, Susan J.
机构：
[1] USC Norris Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA
[2] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia
[3] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada
[4] Vanderbilt Univ, Sch Med, Div Epidemiol, Dept Med, Nashville, TN 37212 USA
[5] Duke Univ Med Ctr, Durham, NC USA
[6] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia
[7] Univ Sydney, Westmead Millennium Inst, Sydney, NSW, Australia
[8] Univ Hosp Erlangen, Erlangen, Germany
[9] Cedars Sinai Med Ctr, Ctr Bioinformat & Funct Genom, Los Angeles, CA 90048 USA
[10] Spanish Natl Canc Res Ctr CNIO, Human Genet Grp, Human Canc Genet Program, Madrid, Spain
[11] Mayo Clin, Rochester, MN USA
[12] Childrens Canc Inst, Randwick, NSW, Australia
[13] Univ Calif Los Angeles, Santa Monica, CA USA
[14] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[15] British Columbia Canc Agcy, Vancouver, BC, Canada
[16] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[17] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[18] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5583
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer
    Zhao, Yue
    Yang, Shao-Min
    Jin, Yu-Lan
    Xiong, Guang-Wu
    Wang, Pin
    Snijders, Antoine M.
    Mao, Jian-Hua
    Zhang, Xiao-Wei
    Hang, Bo
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [2] Prognostic gene expression signature for high-grade serous ovarian cancer
    Millstein, J.
    Budden, T.
    Goode, E. L.
    Anglesio, M. S.
    Talhouk, A.
    Intermaggio, M. P.
    Leong, H. S.
    Chen, S.
    Elatre, W.
    Gilks, B.
    Nazeran, T.
    Volchek, M.
    Bentley, R. C.
    Wang, C.
    Chiu, D. S.
    Kommoss, S.
    Leung, S. C. Y.
    Senz, J.
    Lum, A.
    Chow, V
    Sudderuddin, H.
    Mackenzie, R.
    George, J.
    Fereday, S.
    Hendley, J.
    Traficante, N.
    Steed, H.
    Koziak, J. M.
    Kobel, M.
    McNeish, I. A.
    Goranova, T.
    Ennis, D.
    Macintyre, G.
    De Silva, D. Silva
    Ramon y Cajal, T.
    Garcia-Donas, J.
    Hernando Polo, S.
    Rodriguez, G. C.
    Cushing-Haugen, K. L.
    Harris, H. R.
    Greene, C. S.
    Zelaya, R. A.
    Behrens, S.
    Fortner, R. T.
    Sinn, P.
    Herpel, E.
    Lester, J.
    Lubinski, J.
    Oszurek, O.
    Toloczko, A.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1240 - 1250
  • [3] Identification of a stromal gene expression signature predicting for survival in a cohort of patients with advanced high-grade serous ovarian cancer
    Bonome, Tomas
    Samimi, Goli
    Radonovich, Michael
    Brady, John
    Ghosh, Sue
    Ng, Shu-wing
    Mok, Samuel C.
    Birrer, Michael J.
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : S20 - S21
  • [4] Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma
    Yuan, Dandan
    Zhu, Hong
    Wang, Ting
    Zhang, Yang
    Zheng, Xin
    Qu, Yanjun
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [5] Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma
    Dandan Yuan
    Hong Zhu
    Ting Wang
    Yang Zhang
    Xin Zheng
    Yanjun Qu
    European Journal of Medical Research, 28
  • [6] A stromal-associated gene expression signature predicting for survival in a series of patients with advanced high-grade serous ovarian cancer
    Bonome, T.
    Samimi, G.
    Randonovich, M.
    Brady, J.
    Ghosh, S.
    Ng, S.
    Mok, S. C.
    Birrer, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Identification of a gene signature that can predict lone-term survival in patients with high-grade late stage serous ovarian cancer.
    Bonome, T
    Park, DC
    Hao, K
    Donninger, H
    Radonovich, M
    Brady, J
    Barrett, JC
    Wong, WH
    Welch, WR
    Mok, SC
    Birrer, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 462S - 462S
  • [8] Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer
    Li, Yanli
    Zhang, Jiarong
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2017, 25 (02) : 110 - 116
  • [9] Recurrent gene fusions are common in high-grade serous ovarian cancer.
    Lehtonen, Rainer
    Carpen, Olli
    Huhtinen, Kaisa
    Hynninen, Johanna
    Kaipio, Katja
    Lamminen, Tarja
    Cervera, Alejandra
    Hietanen, Sakari
    Grenman, Seija
    Hautaniemi, Sampsa
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 108 - 108
  • [10] Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer
    Zhang, Yi
    Liu, Jianfang
    Raj-Kumar, Praveen-Kumar
    Sturtz, Lori A.
    Praveen-Kumar, Anupama
    Yang, Howard H.
    Lee, Maxwell P.
    Fantacone-Campbell, J. Leigh
    Hooke, Jeffrey A.
    Kovatich, Albert J.
    Shriver, Craig D.
    Hu, Hai
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (03) : 689 - 698
12345